| Name | Title | Contact Details |
|---|
Saliva Diagnostics Systems is a Brooklyn, NY-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
MJS BioLynx Inc. is a Brockville, ON-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
The DePuy Synthes Companies offer the world’s most comprehensive portfolio of orthopaedic and neuro products and services for joint reconstruction, trauma, spine, sports medicine, neuro, cranio-maxillofacial, power tools and biomaterials. Each of the companies that comprise DePuy Synthes Companies has a celebrated history, and each has evolved to meet the needs of the changing orthopaedics and neuro marketplace. The history that weaves the fabric of the DePuy Synthes Companies is one that is rich with innovation and demonstrates sustained leadership in an ever-changing landscape of patient and professional needs. The content from the DePuy Synthes Companies LinkedIn page is informational only. This content is not a substitute for professional medical advice, diagnosis, or treatment. Seek the advice of your physician with questions regarding a medical condition. Reliance on information provided herein is at your own risk. Comments which are off-topic, offensive, or promotional, are prohibited. Neither DePuy Synthes Companies nor any of its operating companies are responsible for third-party materials appearing on the DePuy Synthes Companies page, including but not limited to linked third-party videos, linked third-party sites, and third-party advertisements. DePuy Synthes Companies does not control or endorse this third-party content and makes no representations regarding its accuracy.
LENSAR, Inc. is a global leader in next-generation femtosecond laser technology for refractive cataract surgery. The LENSAR Laser System offers cataract surgeons precision, accuracy, and efficiency while optimizing overall visual outcomes. LENSAR`s proprietary Augmented Reality technology -- reconstructed 3-D imaging, measurement, and guidance system -- offers quick and easy patient docking and provides high-resolution ocular images in a single scan. This technology facilitates enhanced procedure outcomes by allowing the physician to develop individualized treatment plans including precise laser delivery, and efficient lens fragmentation that can reduce, and potentially eliminate phaco energy. The LENSAR Laser System also offers the industry`s smallest laser footprint and thoughtful ergonomic design that accommodates most operating rooms. The LENSAR Laser System has been cleared by FDA for anterior capsulotomy, lens fragmentation, and corneal and arcuate incisions. For other indications it is an investigational device limited by U.S. law to investigational use only
AgaMatrix is revolutionizing health care. We`ve sold over a million devices, two billion sensors, and we are the first FDA cleared medical device/app that works with iOS. AgaMatrix is an inventor and leader in consumer healthcare technology. With fewer than 150 people, almost 50% in R&D, we develop glucose monitoring and management systems for diabetes. Diabetes related care accounts for 20% of all healthcare spending in the US. Our innovative multidisciplinary technology vision includes iPhone, Android, and web applications supported by a cloud-based, Java back end for data management and exchange between patients and their doctors. Our UI/UX won the prestigious red dot design award. Our proprietary tech platform, protected by 126 granted/pending patents, uses DSP algorithms to double accuracy while reducing cost by 50%. AgaMatrix not only developed the first FDA cleared medical device that connects to an iPhone, but has over a dozen other FDA cleared products, and has sold over 2.5M meters and 3B biosensors. Our products are available in 20,000 retail locations and a worldwide in partnership with Sanofi, the world's largest pharmaceutical company. We`ve been featured by the New York Times and Fast Company, and we work with the world`s largest retailers (Walmart, Kroger, Target) and pharmaceutical companies (Sanofi, Perrigo) to change the way diabetes is treated.